In vitro mitochondrial toxicity of metacavir, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4887-4892

  Zhang, Pinghu ^a   Zhang, Luyong ^a   Jiang, Zhenzhou ^a   Wang, Tao ^a   Chen, Hongkui ^b   Xiong, Yating ^b   Li, Zhan ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Nanjing chang'Ao Pharmaceutical Science and Technology Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LACTIC ACID; METACAVIR; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CONCENTRATION RESPONSE; DNA EXTRACTION; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; ELECTRON MICROSCOPY; ENZYME ACTIVITY; HEPATITIS B; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MITOCHONDRIAL TOXICITY; PRIORITY JOURNAL; RECOMBINANT PLASMID; RESPIRATORY CHAIN; TREATMENT INDICATION;

ANTIVIRAL AGENTS; DNA, MITOCHONDRIAL; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; MITOCHONDRIA; PURINE NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 78049254888     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00794-10     Document Type: Article

References (30)

1. Benbrik, E., P. Chariot, S. Bonavaud, M. Ammi-Said, E. Frisdal, C. Rey, R. Gherardi, and G. Barlovatz-Meimon. 1997. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J. Neurol. Sci. 149:19-25.
2. Birkus, G., M. J. Hitchcock, and T. Cihlar. 2002. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46:716-723.
3. Birkus, G., C. S. Gibbs, and T. Cihlar. 2003. Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells. J. Viral Hepat. 10:50-54.
4. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
5. Brinkman, K., H. ter Hofstede, D. M. Burger, J. A. Smeitink, and P. P. Koopmans. 1998. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12:1735-1744.
6. Brinkman, K., and H. ter Hofstede. 1999. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Rev. 1:140-146.
7. Buffet, M., M. Schwarzinger, B. Amellal, K. Gourlain, P. Bui, M. Prevot, J. Deleuze, J. P. Morini, I. Gorin, V. Calvez, and N. Dupin. 2005. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. J. Clin. Virol. 33:60-64.
8. Carr, A., and D. A. Cooper. 2000. Adverse effects of antiretroviral therapy. Lancet 356:1423-1430.
9. Carr, A., J. Miller, M. Law and, D. A. Cooper. 2000. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14:25-32.
10. Casademont, J., A. Barrientos, J. M. Grau, E. Pedrol, X. Estivill, A. Urbano-Marquez, and V. Nunes. 1996. The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction. Brain 119:1357-1364.
11. Chariot, P., F. Le Maguet, F. J. Authier, D. Labes, F. Poron, and R. Gherardi. 1995. Cytochrome c oxidase deficiency in zidovudine myopathy affects perifascicular muscle fibres and arterial smooth muscle cells. Neuropathol. Appl. Neurobiol. 21:540-547.
12. Chen, C. H., M. Vazquez-Padua, and Y. C. Cheng. 1991. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol. Pharmacol. 39:625-628.
13. Cui, L., S. Yoon, R. S. Schinazi, and J. P. Sommadossi. 1995. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro- β-D-arabinofuranosyl)-5-iodouracil in human liver cells. J. Clin. Invest. 95:555-563.
14. Dalakas, M. C., I. Illa, G. H. Pezeshkpour, J. P. Laukaita, B. Cohen, and J. L. Griffin. 1990. Mitochondrial myopathy caused by long-term zidovudine therapy. N. Engl. J. Med. 322:1098-1105.
15. Dalakas, M. C., M. E. Leon-Monzon, I. Bernardini, W. A. Gahl, and C. A. Jay. 1994. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann. Neurol. 35:482-487.
16. Gourlain, K., B. Amellal, Z. A. Arkoub, N. Dupin, C. Katlama, and V. Calvez. 2003. Quantitative analysis of human mitochondrial DNA using a real-time PCR assay. HIV Med. 4:287-292.
17. Höschele, D. 2006. Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity. Toxicol. In Vitro 20:535-546.
18. Li, Z., X. Huang, Z. Z. Jiang, Y. J. Xiao, C. H. Liu, L. Y. Zhang, B. Shu, J. F. Huang, T. Li, T. Wang, and F. Wang. 2008. A sensitive and specific liquid chromatography-mass spectrometry method for determination of metacavir in rat plasma. J. Chromatogr. B 864:9-14.
19. Lund, K. C., L. L. Peterson, and K. B. Wallace. 2007. Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs. Antimicrob. Agents Chemother. 51:2531-2539.
20. Martin, J. L., C. E. Brown, N. Matthews-Davis, and J. E. Reardon. 1994. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38:2743-2749.
21. Mazzucco, C. E., R. K. Hamatake, R. J. Colonno, and D. J. Tenney. 2008. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob. Agents Chemother. 52:598-605.
22. Mhiri, C., M. Baudrimont, G. Bonne, C. Geny, F. Degoul, C. Marsac, E. Roullet, and R. Gherardi. 1991. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann. Neurol. 29:606-614.
23. Moyle, G. 2000. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin. Ther. 22:911-936.
24. Pan-Zhou, X. R., L. Cui, X. J. Zhou, J. P. Sommadossi, and V. M. Darley-Usmar. 2000. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob. Agents Chemother. 44:496-503.
25. Pinti, M., L. Troiano, M. Nasi, R. Ferraresi, J. Dobrucki, and A. Cossarizza. 2003. Hepatoma HepG2 cells as a model for in vitro studies on mitochondrial toxicity of antiviral drugs: which correlation with the patient? J. Biol. Regul. Homeost. Agents 17:166-171.
26. Slipetz, D. M., J. R. Aprille, P. R. Goodyer, and R. Rozen. 1991. Deficiency of complex III of the mitochondrial respiratory chain in a patient with facioscapulohumeral disease. Am. J. Hum. Genet. 48:502-510.
27. Sundar, K., M. Suarez, P. E. Banogon, and J. M. Shapiro. 1997. Zidovudine induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit. Care Med. 25:1425-1430.
28. Walker, U. A., N. Venhoff, E. C. Koch, M. Olschewski, J. Schneider, and B. Setzer. 2003. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir. Ther. 8:463-470.
29. White, A. J. 2001. Mitochondrial toxicity and HIV therapy Sex. Transm. Infect. 77:158-173.
30. Zeng, W., A. C. Cheng, Z. L. Chen, Q. H. Luo, Y. B. Sun, Z. Li, and F. J. Bin. 2009. In vivo assessment of mitochondrial toxicity of metacavir in rhesus monkeys after three months of intravenous administration. Acta Pharmacol. Sin. 30:1666-1673.